JP2015514061A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514061A5
JP2015514061A5 JP2015500603A JP2015500603A JP2015514061A5 JP 2015514061 A5 JP2015514061 A5 JP 2015514061A5 JP 2015500603 A JP2015500603 A JP 2015500603A JP 2015500603 A JP2015500603 A JP 2015500603A JP 2015514061 A5 JP2015514061 A5 JP 2015514061A5
Authority
JP
Japan
Prior art keywords
alkyl
nrc
haloalkyl
halogen
nrso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015500603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514061A (ja
JP6114815B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/031250 external-priority patent/WO2013138568A1/en
Publication of JP2015514061A publication Critical patent/JP2015514061A/ja
Publication of JP2015514061A5 publication Critical patent/JP2015514061A5/ja
Application granted granted Critical
Publication of JP6114815B2 publication Critical patent/JP6114815B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015500603A 2012-03-16 2013-03-14 肝臓ｘレセプターモジュレーター Expired - Fee Related JP6114815B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612063P 2012-03-16 2012-03-16
US61/612,063 2012-03-16
PCT/US2013/031250 WO2013138568A1 (en) 2012-03-16 2013-03-14 Liver x reception modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017048433A Division JP2017128589A (ja) 2012-03-16 2017-03-14 肝臓ｘレセプターモジュレーター

Publications (3)

Publication Number Publication Date
JP2015514061A JP2015514061A (ja) 2015-05-18
JP2015514061A5 true JP2015514061A5 (https=) 2016-04-28
JP6114815B2 JP6114815B2 (ja) 2017-04-12

Family

ID=47997958

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015500603A Expired - Fee Related JP6114815B2 (ja) 2012-03-16 2013-03-14 肝臓ｘレセプターモジュレーター
JP2017048433A Pending JP2017128589A (ja) 2012-03-16 2017-03-14 肝臓ｘレセプターモジュレーター
JP2018172261A Pending JP2019006813A (ja) 2012-03-16 2018-09-14 肝臓ｘレセプターモジュレーター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017048433A Pending JP2017128589A (ja) 2012-03-16 2017-03-14 肝臓ｘレセプターモジュレーター
JP2018172261A Pending JP2019006813A (ja) 2012-03-16 2018-09-14 肝臓ｘレセプターモジュレーター

Country Status (27)

Country Link
US (5) US9073931B2 (https=)
EP (1) EP2825542B1 (https=)
JP (3) JP6114815B2 (https=)
KR (1) KR102069913B1 (https=)
CN (1) CN104203950B (https=)
AU (1) AU2013232069B2 (https=)
BR (1) BR112014022780A8 (https=)
CA (1) CA2865639C (https=)
CY (1) CY1118323T1 (https=)
DK (1) DK2825542T3 (https=)
EA (1) EA026431B1 (https=)
ES (1) ES2607113T3 (https=)
HR (1) HRP20161690T1 (https=)
HU (1) HUE030785T2 (https=)
IL (2) IL234301A (https=)
LT (1) LT2825542T (https=)
ME (1) ME02660B (https=)
MX (1) MX354820B (https=)
NZ (1) NZ629189A (https=)
PL (1) PL2825542T3 (https=)
PT (1) PT2825542T (https=)
RS (1) RS55532B1 (https=)
SG (1) SG11201405323YA (https=)
SI (1) SI2825542T1 (https=)
SM (2) SMT201700009T1 (https=)
WO (1) WO2013138568A1 (https=)
ZA (1) ZA201406390B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138568A1 (en) * 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
CN104203951B (zh) * 2012-03-16 2016-11-02 生命医药公司 肝x受体调节剂
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
WO2015195922A1 (en) * 2014-06-19 2015-12-23 Vitae Pharmaceuticals, Inc. Compounds for use in treating acute coronary syndrome and related conditions
BR112017002260A2 (pt) * 2014-08-07 2017-11-21 Vitae Pharmaceuticals Inc derivados de piperazina como moduladores do receptor x do fígado
EP3373935B1 (en) 2015-11-12 2021-09-01 Merck Sharp & Dohme Corp. Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use
EP3402477A4 (en) 2016-01-11 2019-08-21 The Rockefeller University METHOD FOR THE TREATMENT OF DISEASES RELATED TO MYELOID-DERIVED SUPPRESSOR CELLS
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
MY198220A (en) 2018-05-15 2023-08-14 Alkahest Inc Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase
JP7654202B2 (ja) * 2019-02-28 2025-04-01 ザ ロックフェラー ユニバーシティー がんの予後及び治療におけるａｐｏｅ遺伝子型決定
EP3999055A1 (en) 2019-07-15 2022-05-25 Novartis AG Methods for treating meibomian gland dysfunction with liver x receptor agonists
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途
US12575690B2 (en) * 2023-07-26 2026-03-17 Brumate, Inc. Keyed straw

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748247A (en) 1986-10-21 1988-05-31 American Home Products Corporation 2-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]alkyl]alkyl]pyrido- and pyrazino-indole-1,3-dione derivatives as histamine H1 antagonists
CA2074163A1 (en) 1990-01-22 1991-07-23 William Thomas Zimmerman Herbicidal sulfonylureas
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
CA2179650C (en) 1993-12-23 2007-10-30 William Francis Heath, Jr. Bisindolemaleimides and their use as protein kinase c inhibitors
AU3831495A (en) 1994-10-20 1996-05-15 American Home Products Corporation Indole derivatives useful as serotonergic agents
AU709631B2 (en) 1996-06-28 1999-09-02 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
WO1998000134A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonists
US6177440B1 (en) 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
FR2761073B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761070B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
DE19802235A1 (de) 1998-01-22 1999-07-29 Bayer Ag Mit tricyclischen Indolen substituierte Oxazolidinone
IL129484A0 (en) 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
DE60018274T2 (de) 1999-05-06 2005-08-04 Neurogen Corp., Branford Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
IT1313593B1 (it) * 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
WO2001030331A2 (en) 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
JP4180365B2 (ja) 2000-07-31 2008-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペラジン誘導体
EP1343768A1 (en) 2000-12-20 2003-09-17 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
FR2829766A1 (fr) 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
CA2471562A1 (en) 2001-12-21 2003-07-24 King Pharmaceuticals Research And Development, Inc. Tyrosyl derivatives and their use as p2x7 receptor modulators
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
US7994196B2 (en) 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
BRPI0509754A (pt) 2004-04-08 2007-10-16 Novartis Ag inibidores de proteìna quinase c para o tratamento de doenças auto-imunes e de rejeição a transplante
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
WO2005113526A2 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
ATE457989T1 (de) * 2004-12-15 2010-03-15 Hoffmann La Roche Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
WO2006072608A2 (en) 2005-01-03 2006-07-13 Universitá Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
CA2615726C (en) 2005-07-14 2014-05-27 Caterina Bissantz Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
JP4882127B2 (ja) * 2005-11-16 2012-02-22 株式会社ジェイテクト 位置調整式ステアリング装置
JP2007137810A (ja) * 2005-11-17 2007-06-07 Sankyo Co Ltd インドール化合物を含有する医薬
DE602006010433D1 (de) 2005-12-09 2009-12-24 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2008122115A1 (en) 2007-04-09 2008-10-16 Methylgene Inc. Inhibitors of histone deacetylase
CA2690748A1 (en) 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
US20100324073A1 (en) * 2007-12-21 2010-12-23 Wyeth Llc Pyrazolo [1,5-A] Pyrimidine Compounds
PE20091439A1 (es) 2008-01-22 2009-10-19 Takeda Pharmaceutical Compuestos triciclicos como antagonistas de crf
US20090192147A1 (en) 2008-01-30 2009-07-30 Wyeth [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW201031665A (en) 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
AU2010257856A1 (en) 2009-06-08 2011-11-03 Grünenthal GmbH Substituted benzimidazoles, benzothiazoles and benzoxazoles
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
MX2012002898A (es) 2009-09-11 2012-04-02 Sunovion Pharmaceuticals Inc Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
WO2011071725A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
KR101302474B1 (ko) 2012-02-20 2013-09-02 주식회사 케이씨씨 내충격성 및 불연성이 우수한 진공단열재용 봉지부재
WO2013138568A1 (en) * 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
CN104203951B (zh) * 2012-03-16 2016-11-02 生命医药公司 肝x受体调节剂

Similar Documents

Publication Publication Date Title
JP2015514061A5 (https=)
JP2015510892A5 (https=)
ME02660B (me) Modulator! jetrenog x receptora
JP2020519654A5 (https=)
HRP20161196T1 (hr) Modulatori jetrenog receptora x
RU2017121588A (ru) Конденсированные бициклические соединения для лечения заболевания
ME01982B (me) 2-anilinobenzimidazol-6-karboksamidi kao anti-inflamatorni agensi
HRP20230052T1 (hr) Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
JP2017531688A5 (https=)
WO2014174524A8 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
JP2014507455A5 (https=)
JP2013542261A5 (https=)
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
JP2015517579A5 (https=)
JP2017528496A5 (https=)
AR084824A1 (es) Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
JP2017522277A5 (https=)
JP2014506907A5 (https=)
JP2013522367A5 (https=)
JP2017537937A5 (https=)
RU2021100040A (ru) Конденсированные бициклические соединения для лечения заболевания
JP2014516033A5 (https=)
ME02685B (me) Kristalni oblik pemirolasta
JP2016540749A5 (https=)
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof